Baby steps towards rescue of Human Brain Project

| July 11, 2014

article image
Cautious efforts to restore unity to the billion-euro Human Brain Project have begun. Both the European Commission and the project’s leaders have now responded to a scorching open letter in which angry neuroscientists condemn the flagship project, and pledge to boycott it. Signed by 156 top neuroscientists, including many research institute directors in Europe, the letter was sent on 7 July to the European Commission, which is funding the project’s first phase. The letter’s authors express concern about both the scientific approach in the neuroscience arm of the project, which aims to simulate brain function in supercomputers, and the general project management.

Spotlight

Microbial Insights, Inc.

Microbial Insights (MI) is a biotechnology laboratory specializing in the development and application of cutting edge molecular biological tools (MBTs) and environmental molecular diagnostics (EMDs) to describe and quantify microbial communities. Environmental Remediation: CENSUS qPCR and QuantArray analyses to quantify bacteria and functional genes involved in contaminant biodegradation including Dehalococcoides. Stable isotope probing (SIP) and Compound Specific Isotope Analysis (CSIA) to conclusively determine whether biodegradation is occurring in situ.

OTHER ARTICLES

Pfizer, BioNTech Plan Clinical Trial for COVID-19 mRNA Vaccine Candidate

Article | April 9, 2020

Pfizer and BioNTech plan to begin human clinical trials on their lead COVID-19 therapeutic candidate, an mRNA vaccine, by the end of this month, the companies said today, through a collaboration that could generate up to $748 million for the German biotech. The companies announced plans last month to partner on BNT162, the first treatment to emerge from BioNTech’s accelerated COVID-19-focused development program, “Project Lightspeed.” BioNTech and Pfizer established collaboration intended to draw upon BioNTech’s proprietary mRNA vaccine platforms, and Pfizer’s expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network.

Read More

Selexis Cell Line Development Strategies

Article | February 11, 2020

In today’s biotechnology landscape, to be competitive, meet regulations, and achieve market demands, “we must apply Bioprocessing 4.0,” said Igor Fisch, PhD, CEO, Selexis. In fact, in the last decade, “Selexis has evolved from cloning by limiting dilution to automated cell selection to nanofluidic chips and from monoclonality assessment by statistical calculation to proprietary bioinformatic analysis,” he added. Single-use processing systems are an expanding part of the biomanufacturing world; as such, they are a major component of Bioprocessing 4.0. “At Selexis, we use single use throughout our cell line development workflow. Currently, we have incorporated single-use automated bioprocessing systems such as ambr® and the Beacon® optofluidic platform for accelerated cell line development. By using these systems and optimizing our parameters, we were able to achieve high titers in shake flasks. Additionally, the Beacon systems integrate miniaturized cell culture with high-throughput liquid handling automation and cell imaging. This allows us to control, adjust, and monitor programs at the same time,” noted Fisch.

Read More

2 Small-Cap Biotech Stocks You Haven't Heard of, But Should Know About

Article | April 17, 2020

With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks that aren't actively involved in developing tests, vaccines or treatments for COVID-19. Vaccine developers, protective equipment producers, and healthcare service providers are all attracting plenty of attention during this pandemic, but there are just as many promising biotech stocks that aren't involved in these areas. Here are two such companies that you might have missed, but they deserve a spot on your watch list.

Read More

Wisconsin biotech companies could play key roles in long-term economic recovery from COVID-19 pandemic

Article | April 19, 2020

Whether it’s called a modern “Manhattan Project” or a medical moon shot, the concept of long-term economic recovery rests on how confident people are they won’t risk serious illness by venturing forth in public again. Wisconsin stands to be a significant part of such an undertaking, whatever it’s called. The shorter-term debate is well under way over the gradual lifting of COVID-19 emergency rules, such as the now-extended “safer-at-home” order in Wisconsin. At least a dozen states, including regional coalitions on the East and West coasts, are exploring next steps as they seek to balance responses to the virus with calls for reopening the economy, at least, in part. Wisconsin’s ability to shape longer-term responses will come from private and public resources, which range from companies engaged in production of diagnostics.

Read More

Spotlight

Microbial Insights, Inc.

Microbial Insights (MI) is a biotechnology laboratory specializing in the development and application of cutting edge molecular biological tools (MBTs) and environmental molecular diagnostics (EMDs) to describe and quantify microbial communities. Environmental Remediation: CENSUS qPCR and QuantArray analyses to quantify bacteria and functional genes involved in contaminant biodegradation including Dehalococcoides. Stable isotope probing (SIP) and Compound Specific Isotope Analysis (CSIA) to conclusively determine whether biodegradation is occurring in situ.

Events